Physician profile
Michelle Egbert
NPI 1205420056
$4,426.43
in general payments reported to CMS, 2019-2025
26 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $434 · 2023: $996 · 2024: $1,537 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.72 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.17 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $470.03 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $396.79 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $329.19 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $321.81 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.66 | 2022-2025 | Caplyta |
| Lundbeck LLC | $281.06 | 2022-2025 | Rexulti, Brintellix |
| Otsuka America Pharmaceutical, INC. | $269.34 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $223.96 | 2023-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $186.11 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $178.91 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $89.73 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $89.24 | 2022-2025 | Trintellix |
| Tempus Ai, INC | $66.78 | 2024 | |
| Indivior INC. | $61.82 | 2022-2024 | Perseris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $50.65 | 2022 | |
| Sage Therapeutics, LLC | $37.79 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $30.06 | 2024 | Qelbree |
| Corium, LLC | $22.14 | 2022 | |
| Livanova USA, INC. | $20.98 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Braeburn INC. | $20.77 | 2025 | Brixadi |
| Bausch Health US, LLC | $19.99 | 2023 | Aplenzin |
| Janssen Scientific Affairs, LLC | $17.64 | 2025 | Invega Sustenna |
| Collegium Pharmaceutical, INC. | $17.45 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $17.03 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Egbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.